Clermont et al demonstrated that plasma kallikrein contributes to retinal vascular permeability [13], while other studies have shown that tissue kallikrein improves diabetic retinopathy by inhibiting retinal vascular permeability and vascular endothelial growth factor (VEGF) increases in rat models of diabetes [14]. This evidence concerns the gene KLK4 and diabetes mellitus.